Osivelotor is an oral investigational drug for the treatment of sickle cell disease (SCD) designed to inhibit hemoglobin polymerization. In a phase 1, open-label ADME study conducted in healthy participants at ICON’s cli...
-
ICON wins Best Contract Research Organisation at the annual Scrip Awards 2017
ICON recognised for partnership capabilities and innovation in patient recruitment.
-
ICON launches FIRECREST Pre-Screen
FIRECREST Pre-Screen improves sponsor visibility of patient access
-
MediMedia Managed Markets wins two gold industry awards
The ICON company won the gold awards for Data Analytics and Healthcare Communications.
-
ICON contributes to major study on treatment for traumatic brain injury
Recommendations from the longitudinal observational research study will be presented today at the European Parliament.
-
ICON reveals voice-assistant applications for clinical trials
The new proof-of-concept developments were revealed at the ISPOR Annual European Congress.
-
ICON acquires Mapi Group
Mapi Group is a leading Patient-Centered Health Outcomes Research and Commercialisation company.
-
ICON wins eLearning and Animation Awards for its FIRECREST Digital Solutions
FIRECREST was awarded gold in the International eLearning Awards (IELA) in the blended learning category, and received a silver award for digital animation in the Summit International Awards.
-
Best Partnership award win from Pharma Times
ICON and Regeneron Win Best Partnership in Clinical Research Award from PharmaTimes.
-
ICON named by Forbes as One of the Best Employers in America
Forbes ranking of top employers drawn from a survey of 30,000 US employees in 25 industry sectors
-
ICON awarded Best CRO at World Vaccine Congress 2017
ICON recognised for continually setting standards of excellence in vaccine development
